Clinical Trial Update: Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 efficacy and safety trial of MC-1101 for nonexudative age-related macular degeneration has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• MC-1101

Snippet

Sponsor: MacuCLEAR, Inc. | Conditions: Nonexudative Age Related Macular Degeneration | Phase 2, Phase 3 | Status: TERMINATED